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The association between differentiated thyroid carcinoma (DTC) and chronic lymphocytic thyroiditis 
(CLT) has been reported in literature. 
Aim: To evaluate the incidence of this association and to determine whether the CLT may influence 
on the early initial staging of DTC when associated with other variable risks. 
Study design: Historical (retrospective) cohort. 
Materials and Methods: Fifty two patients with DTC were evaluated from 1999 to 2009. They 
were divided into two groups. The first group had 35 patients with DTC without DLT; the second 
had 17 patients with CLT. Total thyroidectomy was the treatment chosen for all patients. Similarities 
shared in both groups such as age, gender, histological tumor type, tumor diameter, regional only 
or with distant metastases, extrathyroidal invasion, multifocality and presence of tumor capsule were 
considered. T-Student tests and Chi-square tests were applied to analyze the data. 
Results: The incidence of DTC without CLT was higher that of DTC+CLT (p=0.0126). We noticed 
no statistic differences between the common variables analyzed. 
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INTRODUCTION
Thyroid cancer is responsible for about 1% of the 
new cases of diagnosed malignant diseases1; and is divided 
according to histological type into papilliferous, follicular, 
undifferentiated, a little differentiated and malignant lym-
phoma, among others2.
papilliferous and the follicular carcinoma are also 
called thyroid differentiated carcinoma (TDC), although 
they have distinct clinical, histological and biological 
patterns3. They correspond to approximately 90% of the 
cases of malignant neoplasia of the thyroid1,4. When diag-
nosed early on, TDC is a tumor which is usually curable5. 
Studies point out that these cancers have a cure rate of 
approximately 80%, while 20% will have local recurrence 
and 5 to 10% will develop distant metastasis4.
Besides the classical form, the papilliferous cancers 
have distinct histological variants identified as: follicular, 
trabecular, insular, solid, of high cells, of columnar cells, 
diffuse sclerosing, oxyphilic, amongst others also reported 
in the literature2,6. These patterns, despite controversial 
and still not standardized, are not necessarily exclusive, 
since one single tumor may fit the description of multiple 
variants2. The majority has only morphological differences, 
and it does not always have significant prognostic value2. 
The follicular carcinoma is further divided according to in-
vasion and growth patterns2,6. As to invasion, we know two 
forms: minimally invasive and broadly or largely invasive2,6. 
The growth pattern may vary from one well differentiated 
form to another which is not so well differentiated2,6.
The TDC patient may be classified into high, low 
and very low risk1. When analyzing the initial tumor, it is 
very important to know what is its likely prognosis7. In 
recent years, the search for factors which can influence 
prognosis has been a constant, since they impact directly 
on the identification of patients who have a more aggressi-
ve disease, as well as its treatment and follow up8. Multiple 
series of cases have been assessed and numerous staging 
classifications have been proposed taking into account risk 
and prognostic factors (TNM, EORTC, UICC/AJCC, AGES, 
AMES, MACIS, Clinical classification, Ohio)3,9-16. Nonethe-
less, the relative impact of each one of these indicators is 
yet to be clearly defined.
Many reports have stressed the concurrence betwe-
en chronic lymphocytic thyroiditis (CLT) and TDC, which 
has been pointed as a prognostic factor for this type of 
neoplasia17-21.. CLT is a disorder stemming from the fact 
that T suppressor lymphocytes are rendered incapable of 
destroying clones of lymphocytes sensitized by thyroid 
antigens, with consequent cytotoxicity mediated by natural 
killer cells and the interaction of T-Helper lymphocytes 
with lymphocytes B, producing antibodies against thyroid 
components2.
Studies have investigated the possible relationship 
between the chronic lymphocytic infiltrate expression 
and the degree of histological aggressiveness in thyroid 
tumors18,19,21,22. Notwithstanding, most of these papers 
assessed only the lymphocitic thyroid disease associated 
with well differentiated carcinoma in general, without 
investigating whether these lymphocytic infiltrates, when 
associated with the other risk factors, would be associated 
to low or high risk. The goal of the present paper was 
to establish the relative frequency of CLT in patients with 
TDC, and whether the CLT in a multivariate risk analysis 
could influence tumor staging and, indirectly, the prognosis 
of this disease.
MATERIALS AND METHODS
We carried out a historical cohort study (retrospec-
tive), encompassing a period of 10 years - between July of 
1999 and May of 2009, when we analyzed the pathology 
reports from the medical charts of 54 patients diagnosed 
with TDC who were submitted to total thyroidectomy, 
from whom we had the following data: gender, age upon 
diagnosis, tumor diameter, tumor capsule findings, thyroid 
invasion, multifocality, locoregional metastasis, histology 
pattern, chronic lymphocitic thyroiditis and distant metas-
tasis; and these were the inclusion criteria for the present 
study. Two charts were excluded for not having complete 
data. The material utilized was obtained from files from 
the Private Clinic and the Pathology Lab.
These charts and reports were separated in two 
groups: the first with TDC diagnosis, and the second were 
those with TDC associated with CLT. All the patients were 
submitted to total thyroidectomy, with or without neck 
lymph node dissection, and radiotherapy. Neck dissection 
was indicated for those patients who had clinical signs 
of lymph node involvement, found in pre-op ultrasound 
exam or during surgery.
TDC diagnosis and that of its variants was based on 
the criteria defined by the World Health Organization in 
2004, later modified2,6. CLT was defined as the presence 
of lymphocitic infiltrate, varying from islands in the tumor 
itself or around it, all the way to large infiltrates, also 
including germinative centers23. Patients with the classic 
Hashimoto’s Thyroiditis (HT) were also included in the 
study as having lymphocitic thyroiditis.
The material obtained from the thyroidectomies was 
analyzed by 4 pathologists of the same team, by means of 
macroscopic and microscopic assessments. The later by 
means of paraffin block slides, in histologic cross-sections 
dyed by the hematoxylin-eosin technique, using the elec-
tronic microscope.
The distant metastasis variable was assessed after 
surgery by means of a full body scan with radioactive 
iodine.
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Tumor staging (Table 1) and risk stratification (Table 
2) were assessed in accordance with the classification from 
the American Joint Committee on Cancer (AJCC) / Tumor 
Nodes Metastasis (TNM)24,25.
Variables common to groups TDC and TDC + CLT 
were statistically analyzed in order to look for differences 
between them.
For database management, statistical calculations 
and to create the tables and graphs we used Microsoft 
Excel® version 2003. The t Student test was used in order 
to compare the groups as the quantitative variables age 
and tumor diameter. In order to associated the qualitative 
variables: gender, extrathyroid invasion, tumor capsule, 
multifocality, distant metastasis, locoregional metastasis, 
histological pattern and tumor staging we used the chi-
squared test. In all the statistical tests we used the 5% 
(p<0,05) significance level.
This study was approved by the Ethics in Research 
Committee of the Institution, under protocol # 057/09.
RESULTS
All the charts were from patients with papilliferous 
carcinoma. Of these, 17 (33%) had TDC together with CLT, 
and 35 (67%) had TDC without CLT (p=0.01) (Table 3). 
We found no case of follicular carcinoma.
The ages varied between 14 and 80 years, with 
a mean of 45.9 years. There was one case of TDC in a 
14-year-old girl. In the TDC+CLT group, the youngest pa-
tient was a 22 year-old woman. There was no significant 
difference between the groups as far as age is concerned 
(Table 4). In the TDC group, tumor diameter varied be-
tween 0.3 and 6 cm, in the TDC_CLT group, tumor size 
was smaller - 0.4 and 3.5 cm (p=0.8) (Table 4).
The microcarcinoma (tumor smaller than 1cm), 
was most frequently found in the TDC+CLT group, when 
compared to the TDC group: 11 (64.7%) and 18 (51.4%), 
respectively (p=0.5) (Table 5).
The results from the multivariate analysis are de-
picted on Table 6.
The distribution by tumor diameter, within each 
group was: 28 cases (80%) smaller than or equal to 2 cm 
in the TDC group, and 12 (70.6%) in the TDC + CLT; 6 
cases (17.1%) larger than 2cm and smaller than or equal to 
4cm in the TDC group, and 5 (29.5%) in the TDC + CLT. 
There was only one case in which the tumor was larger 
Table 1. TNM classification for thyroid cancer 
T (TUMOR) N (LYMPH NODE METASTASES) M (DISTANT METASTASES)
T1 £ 2 cm (T1a £ 1cm T1b 1-2 cm) N0 absent M0 absent
T2 2-4 cm N1a metastases at VI level M1 distant metastases
T3 > 4cm confined to the thyroid or with minimum extrathyroid 
invasion
N1b neck metastases (lateral) or in the 
upper mediastinum
 
T4a invading subcutaneous tissue, larynx, trachea, esophagus, 
or laryngeal recurrent
  
T4b invading pre-vertebral fascia or involving the carotid or me-
diastinal vessels
  
Tx unknown size without extrathyroid invasion Nx lymph nodes not assessed Mx not assessed
TNM: Classification proposed by the American Joint Committee on Cancer (2002).
Table 2. Staging of undifferentiated thyroid tumors.
Stage < 45 years ³ 45 years
Papillary or follicular carcinoma   
I Any  T, any N, M0 T1, N0, M0
II Any T, any N, M1 T2, N0, M0
III - T3, N0, M0
T1/T2/T3, N1a, M0
IV A - T4a, any N, M0
T1/T2/T3, N1b, M0
IV B - T4b, any N, M0
IV C - any T, any N, M1
Classification proposed by the American Joint Committee on Cancer (2002).
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than 4cm, it happened in the TDC group. There were no 
significant differences between patients in the TDC group 
in relation to the greater tumor diameter.
In the TDC and TDC+CLT groups there was a di-
fference which was only proportional to the presence or 
absence of the capsule. In the TDC group, 37.1% of the 
patients  had the capsule, while in the TDC+CLT group, 
29.4% only had a capsule (p=0.5).
We can notice a predominance of multifocality in 
the TDC+CLT group, however such difference was not 
statistically significant.
In the patients with TDC+CLT, we noticed a higher 
frequency of extrathyroid invasion (17.1% vs. 23.5%), ho-
wever with a lower rate of locoregional metastasis (17.7% 
vs. 20%). No patient in this sample had distant metastasis.
As to carcinoma distribution according to histology, 
39 cases (75%) were classic TDC, and 13 cases were its 
variants. We also noticed a predominance of the follicular 
variant, 12 cases (23.1%), and there was only one case 
(1.9%) of the oxyphilic cells variant, which occurred in 
the TDC group (p=0.6) (Table 6).
There was a predominance of females, 48 cases 
(92.3%), and 4 cases (7.7%) of males. In the TDC group, 
32 (91.4%) patients were females, and in the TDC+CLT, 
16 (94.1%) were females and only 1(5.9%) patient was 
male (p=0.8).
In both groups the initial stages I and II were 
predominant, without considerable statistical difference 
(Table 7).
DISCUSSION
Since its first publication, the TDC and CLT relation 
is controversial, and it has been largely discussed in the 
literature, with results varying between those which did not 
prove the association26 and others in which it is clear17-21,27. 
In many of these series, the papilliferous carcinoma was 
the predominant histological pattern, and this was also 
true in the present paper. In 32.69% of the cases there 
was an association between the CLT and the TDC, which 
coincides with data reported in the literature.
It is uncertain whether the coexisting thyroiditis 
could be the cause or consequence of the thyroid carcino-
ma, and whether it influences its staging and its prognosis 
indirectly.
It is believed that CLT induces the malignant 
transformation because it stimulates mitosis and follicular 
epithelium proliferation through cell necrosis, caused 
by the chronic infiltration of lymphocytes and hormonal 
thyroid stimulation, or by a partial disorganization of the 
antitumor autoimmune surveillance18. On the other hand, 
some authors consider the lymphocytic infiltration process 
as benign; thus inferring that CLT would not be a pre-
malignant lesion, but rather an autoimmune mechanism 
involved in the TDC28.  It has been reported that the TDC 
has a better prognosis when associated with the CLT29.
In this analysis we did not find significant differen-
ces between the TDC and TDC+CLT groups in relation to 
tumor diameter, although there are papers proving the CLT 
association to initial stage tumors30. Other authors also did 
not find significant associations comparing multifocality, 
age and gender between patients with and without lym-
phocytic infiltrates27. One study reported that 30% of the 
patients with thyroid papilliferous carcinoma had coexis-
ting CLT. However, the better prognosis reported would 
be more related to a minimum protective effect, since it 
is more common to young female patients31. Papers have 
shown a lower incidence of distant metastasis and disease 
recurrence in patients with associated CLT29.
Better prognoses are: those microcarcinoma or 
encapsulated tumors: the classic and follicular variants 
are of medium prognosis and the high cells and column 
Table 3. Patient distribution according to the presence of CLT (chro-
nic lymphocitic thyroiditis).






Yes 17 32,69 (19,94 - 45,44)
No 35 67,31 (54,56 - 80,06)
Total 52 100,00  
(c² = 6,23; gl = 1; p = 0,0126)
Table 4. Comparing the groups in relation to patient age and tumor 
diameter.
Group age(years) Diameter(cm)
 N  Mean  Mean
TDC 35 43;1 (14-80)  1,4(0,3-6)
TDC + CLT 17 51;3(22-76)  1,3(0,4-3,5)
Total 52 45;9(14-80)  1,33(0,3-6)
Age: (p = 0.1); Tumor diameter: (p = 0.8794). Comparison through 
the t Student test.
CLT: chronic lymphocitic thyroiditis; TDC: thyroid differentiated car-
cinoma; TDC+CLT: thyroid differentiated carcinoma associated with 
chronic lymphocitic thyroiditis.
Table 5. Distribution of the patients with TDC (thyroid differentiated 






No 17 (48,6%) 6 (35,3%) 23 (44,2%)
Yes 18 (51,4%) 11 (64,7%) 29 (55,8%)
Total 35 (100,0%) 17 (100,0%) 52 (100,0%)
(c² = 0,37; gl = 1; p = 0,54407)
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cells are those considered the worst prognosis8. Although 
the results were not statistically significant, in the present 
study we found 64.7% microcarcinomas in the TDC+CLT 
group vs. 51.4% in the TDC group.
Although the CLT and TDC association has been 
broadly proven in many papers, the following aspects 
remain uncertain:
1. Do these two thyroid disorders share a common 
etiology?
2. Does the CLT affect the TDC biological behavior?
3. Do the chronic lymphocitic infiltrates represent 
a host immune response to the tumor or is it an isolate 
occurrence?
Studies with larger samples and with long term 
follow up are still necessary in order to clear up these 
issues.
Nonetheless, these authors believe that the 
TDC+CLT cases are of low risk and good prognosis, since 
most of these patients were staged as initial, implying a 
possible protective role of the lymphocitic infiltrate.
CONCLUSION
1. CLT associated with the TDC happened in 17 
(33%) of the 52 patients with differentiated carcinomas 
of the thyroid.
2. The CLT did not influence tumor staging in pa-
tients with TDC.




TDC + CLT n (%)
TOTAL 
n (%)
Comparing TDC with and 
without CLT (p)*
Tumor diameter
£ 2 cm 28 (80%) 12 (70,6%) 40 (76,9%) 0,48878
> 2 e £ 4 cm 6 (17,1%) 5 (29,4%) 11 (21,2%)
> 4 cm 1 (2,9%) 0 (0%) 1 (1,9%)
Tumor capsule
Absent 22 (62,9%) 12 (70,6%) 34 (65,4%) 0,58253
Present 13 (37,1%) 5 (29,4%) 18 (34,6%)
Multifocality
No 25 (71,4%) 9 (52,9%) 34 (65,4%) 0,31548
Yes 10 (28,6%) 8 (47,1%) 18 (34,6%)
Extrathyroid invasion
No 29 (82,9%) 13 (76,5%) 42 (80,8%) 0,86257
Yes 6 (17,1%) 4 (23,5%) 10 (19,2%)
Distant metastasis
No 35 (100%) 17 (100%) 52 (100%) -
Yes - - -
Locoregional 
metastasis
No 28 (80%) 14 (82,4%) 42 (80,8%) 0,86257
Yes 7 (20%) 3 (17,7%) 10 (19,2%)
Histology pattern
Papilliferous Classic 25 (71,4%) 14 (82,4%) 39 (75%) 0,60943
Papilliferous follicular 
variant
9 (25,7%) 3 (17,7%) 12 (23,1%)
Papilliferous oxyphilic 
variant
1 (2,9%) 0 (0%) 1 (1,9%)
Patient variables     
Gender
Females 32 (91,4%) 16 (94,1%) 48 (92,3%) 0,83105
Males 3 (8,6%) 1 (5,9%) 4 (7,7%)
Age in years
< 45 years 17 (48,6%) 4 (23,5%) 21 (40,4%) 0,15412
³ 45 years 18 (51,4%) 13 (76,5%) 31 (59,6%)
*Association between the variables done through the chi-squared test. TDC: thyroid differentiated carcinoma. TDC + CLT: thyroid differentiated 
carcinoma associated with chronic lymphocitic thyroiditis.







TNM classification   
NS
Stage I 11 (26,8%) 30 (73,2%)
Stage II 2 (66,7%) 1 (33,3%)
Stage III 1 (50%) 1 (50%)
Stage IV a 3 (50%) 3 (50%)
TDC: thyroid differentiated carcinoma; CLT: chronic lymphocitic thyroi-
ditis, P = NS: statistically non-significant, TNM: Classification proposed 
by the American Joint Committee on Cancer (2002).
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3. There were no statistical differences between the 
variables: age, gender, histology pattern, tumor diameter, 
locoregional or distant metastasis, extrathyroid invasion, 
multifocality, and the presence of tumor capsule in the 
groups with and without CLT.
4. Considering the risk factors all together, most of 
the TDC+CLT cases were staged as initial. 
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